Category Archives: Gene Medicine

ZUG, Switzerland and BOSTON, Sept. 28, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130, the Companys wholly-owned allogeneic CAR T cell therapy targeting CD70, for the treatment of Mycosis Fungoides and Szary Syndrome (MF/SS).

The RMAT designation is an important milestone for the CTX130 program that recognizes the transformative potential of our cell therapy in patients with T-cell lymphomas based upon encouraging clinical data to date, said Phuong Khanh (P.K.) Morrow, M.D., FACP, Chief Medical Officer of CRISPR Therapeutics. "We continue to work with a sense of urgency to bring our broad portfolio of allogeneic cell therapies to patients in need.

Established under the 21st Century Cures Act, RMAT designation is a dedicated program designed to expedite the drug development and review processes for promising pipeline products, including genetic therapies. A regenerative medicine therapy is eligible for RMAT designation if it is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or therapy has the potential to address unmet medical needs for such disease or condition. Similar to Breakthrough Therapy designation, RMAT designation provides the benefits of intensive FDA guidance on efficient drug development, including the ability for early interactions with FDA to discuss surrogate or intermediate endpoints, potential ways to support accelerated approval and satisfy post-approval requirements, potential priority review of the biologics license application (BLA) and other opportunities to expedite development and review.

About CTX130 and COBALT TrialsCTX130, a wholly-owned program of CRISPR Therapeutics, is a healthy donor-derived gene-edited allogeneic CAR T investigational therapy targeting Cluster of Differentiation 70, or CD70, an antigen expressed on various solid tumors and hematologic malignancies. CTX130 is being investigated in two ongoing independent Phase 1 single-arm, multi-center, open-label clinical trials that are designed to assess the safety and efficacy of several dose levels of CTX130 in adult patients. The COBALT-LYM trial is evaluating the safety and efficacy of CTX130 for the treatment of relapsed or refractory T or B cell malignancies. The COBALT-RCC trial is evaluating the safety and efficacy of CTX130 for the treatment of relapsed or refractory renal cell carcinoma. CTX130 has received Orphan Drug and Regenerative Medicine Advanced Therapy designations from the FDA.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

CRISPR Forward-Looking StatementThis press release may contain a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements made by Dr. Morrow in this press release, as well as regarding CRISPR Therapeutics expectations about any or all of the following: (i) the status of clinical trials and discussions with regulatory authorities related to product candidates under development by CRISPR Therapeutics including, without limitation, expectations regarding the benefits of RMAT designation; and (ii) the therapeutic value, development, and commercial potential of CRISPR/Cas9 gene editing technologies and therapies. Without limiting the foregoing, the words believes, anticipates, plans, expects and similar expressions are intended to identify forward-looking statements. You are cautioned that forward-looking statements are inherently uncertain. Although CRISPR Therapeutics believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the potential for initial and preliminary data from any clinical trial and initial data from a limited number of patients not to be indicative of final trial results; the potential that clinical trial results may not be favorable; potential impacts due to the coronavirus pandemic, such as the timing and progress of clinical trials; that future competitive or other market factors may adversely affect the commercial potential for CRISPR Therapeutics product candidates; uncertainties regarding the intellectual property protection for CRISPR Therapeutics technology and intellectual property belonging to third parties, and the outcome of proceedings (such as an interference, an opposition or a similar proceeding) involving all or any portion of such intellectual property; and those risks and uncertainties described under the heading "Risk Factors" in CRISPR Therapeutics most recent annual report on Form 10-K, quarterly report on Form 10-Q and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission, which are available on the SEC's website at http://www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. CRISPR Therapeutics disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

CRISPR THERAPEUTICS standard character mark and design logo, CTX130 and COBALT are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact:Susan Kim+1-617-307-7503susan.kim@crisprtx.com

Media Contact:Rachel Eides+1-617-315-4493rachel.eides@crisprtx.com

View original post here:
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130 for the Treatment of Cutaneous T-Cell...

Of the 1.5 million people living with lupus in the United States, 90% are women. This disease turns the bodys immune system against itself, potentially causing extreme pain, fatigue, difficulty thinking clearly, and cardiovascular disease.

Officially known as systemic lupus erythematosus, lupus is distinct among autoimmune diseases in the way circulating antibodies proteins that when functioning properly help to protect against disease react against DNA, the bodys instructions for building cells and passing traits from parents to children.

Drs. Peter M. Glazer and James Hansen discovered that one specific lupus antibody, known as 3E10, can penetrate cancer cells and make them sensitive to and killed by standard radiation and chemotherapy methods. Notably, this technique has shown significant effectiveness in killing cancer cells with DNA repair deficiencies, such as those with mutations in the tumor-suppressing BRCA2 gene that lead to higher rates of breast and ovarian cancer.

Now, nearly a decade since this discovery and with he help of a grant from Womens Health Research at Yale, researchers are close to advancing a treatment toward clinical trials while learning more about how this lupus antibody penetrates and kills cancer cells.

This discovery has unlocked promising new pathways for treatment of BRCA-related cancers that affect so many women around the world, said Glazer, the Robert E. Hunter Professor of Therapeutic Radiology, professor of genetics, and chair of the Department of Therapeutic Radiology. We have learned a great deal about how 3E10 interacts with DNA, and we continue to explore how this knowledge could be used to create therapies for other types of difficult-to-treat cancers.

Dr. Glazer and his colleague Dr. James E. Hansen, associate professor of therapeutic radiology, licensed the rights for their antibody discovery to a company, Patrys, Ltd., that has validated the work and developed 3E10 as a cancer therapy for human use. An earlier human study in Switzerland attempting to use 3E10 as a vaccine for lupus had already demonstrated that it is nontoxic. Phase 1 clinical trials could begin as early as next year, Dr. Glazer said, likely for patients with cancers related to mutations of BRCA1/2 genes or of another tumor suppressing gene known as PTEN.

This is very promising, Glazer said. I think it will be important to identify the right subgroup of patients for which this is most effective.

After publishing the results, Dr. Glazer and his colleagues leveraged the data to obtain a pair of large multiyear grants from the National Institutes of Health. With this funding and the help of Yale graduate student Audrey Turchick, the team has discovered that inside a cancer cell, 3E10 sticks to a DNA repair protein called RAD51. This causes the lethality for cancer cells that are deficient in BRCA1 and BRCA2 genes by preventing the cells from conducting the routine DNA repair necessary to sustain themselves.

With ongoing funding from the NIH, Dr. Glazers team, including structural biologist Dr. Franziska Bleichert, is building on these findings to enhance the anti-cancer potency of 3E10 and develop therapeutic strategies by identifying ways for the antibody to stick more strongly to RAD51.

In addition, an MD/PhD student in the lab, Elias Quijano, helped identify the capacity of 3E10 to bind with RNA a type of molecule used to carry out DNA instructions and carry RNA into a cancer cell, potentially with instructions that can kill the cell. Quijano and Drs. Glazer, Stephen Squinto, and Bruce Turner co-founded Gennao Bio, a company seeking to develop this method of cancer-fighting therapy.

This was an unexpected discovery that turns out may be very useful, Glazer said. We have some data showing the efficacy of this method against tumors in a laboratory model. It is a versatile platform, because it can deliver different types of RNA in a similar way to how the COVID-19 mRNA vaccines work.

The research continues, thanks in large part to the investment WHRY made so many years ago.

I think that type of funding is extremely valuable, Glazer said of his WHRY grant. It allowed us to do the sets of exploratory experiments we needed to do to demonstrate our approach was viable and get the larger grants. We showed this is feasible, this is promising.

Original post:
Fighting Breast and Ovarian Cancer With a Lupus Antibody - Yale School of Medicine

SAN FRANCISCO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, todayannounced that the California Institute for Regenerative Medicine (CIRM) has awarded Excision a $6.85 million grant to support the clinical development of the EBT-101 program for human immunodeficiency virus type 1 (HIV-1).

Daniel Dornbusch, Chief Executive Officer of Excision, commented, We are honored that CIRM has recognized the potential value of the EBT-101 program and our dual-guide RNA CRISPR approach to developing curative therapies for HIV-1 as well as other serious viral diseases with significant unmet needs. The CIRM grant provides further validation for the EBT-101 clinical trial, which is the first ever to evaluate an in vivo CRISPR-based therapy in an infectious disease. The grant will provide Excision with important funding to advance the trial and potentially demonstrate the safety and efficacy of removing viral DNA from people affected by the HIV pandemic.

Excision recently reported the first participant in the EBT-101 Phase 1/2 clinical trial was dosed in July 2022, with initial findings indicating the therapeutic has been well tolerated to-date. The participant continues to be monitored for safety and is expected to qualify for analytical treatment interruption (ATI) of their background anti-retroviral therapy (ART) in an evaluation of a potential cure.

To date only a handful of people have been cured of HIV/AIDS, so this proposal of using gene editing to eliminate the virus could be transformative, says Maria T. Millan, MD, President and CEO of CIRM. In California alone there are almost 140,000 people living with HIV. HIV infection continues to disproportionately impact marginalized populations, many of whom are unable to access the medications that keep the virus under control. A functional cure for HIV would have an enormous impact on these communities, and others around the world.

About EBT-101EBT-101 is a unique, in vivo CRISPR-based therapeutic designed to cure HIV infections after a single intravenous infusion. EBT-101 employs an adeno-associated virus (AAV) to deliver CRISPR-Cas9 and dual guide RNAs, enabling a multiplex editing approach that simultaneously targets three distinct sites within the HIV genome. This allows for the excision of large portions of the HIV genome, thereby minimizing potential viral escape.

About the EBT-101 Clinical ProgramThe EBT-101 Phase 1/2 trial is an open-label, multi-center single ascending dose study designed to evaluate the safety, tolerability and preliminary efficacy of EBT-101 in approximately nine participants with HIV-1 who are suppressed on antiretroviral therapy. The clinical program is supported by preclinical studies that included positive long-term non-human primate safety data and efficacy data in humanized mice showing the potential to cure HIV when treated with EBT-101. The primary objective of the trial is to assess the safety and tolerability of a single dose of EBT-101 in study participants with undetectable viral load on antiretroviral therapy (ART). Biodistribution, pharmacodynamic, and efficacy assessments will also be conducted. All participants will be assessed for eligibility for an analytical treatment interruption (ATI) of their background ART at Week 12 post EBT-101 administration. Following the initial 48-week follow up period, all participants will be enrolled into a long-term follow up protocol. For more information, see ClinicalTrials.gov identifiers NCT05144386 (Phase 1/2 trial) and NCT05143307 (long-term follow up protocol).

About CIRMAt CIRM, we never forget that we were created by the people of California to accelerate stem cell treatments to patients with unmet medical needs, and act with a sense of urgency to succeed in that mission.To meet this challenge, our team of highly trained and experienced professionals actively partners with both academia and industry in a hands-on, entrepreneurial environment to fast track the development of todays most promising stem cell technologies.With $5.5 billion in funding and more than 150 active stem cell programs in our portfolio, CIRM is one of the worlds largest institutions dedicated to helping people by bringing the future of cellular medicine closer to reality. For more information go towww.cirm.ca.gov.

About Excision BioTherapeutics, Inc.Excision BioTherapeutics, Inc. is a clinical-stage biotechnology company developing CRISPR-based therapiesas potentialcures for viral infectious diseases. EBT-101, the Companys lead program, is anin vivoCRISPR-based therapeutic designed to cure HIV infections after a single intravenous infusion. Excisions pipeline unites next-generation CRISPR nucleases with a novel gene editing approach to develop curative therapies for Herpes Virus, JC Virus,which causes PML, and Hepatitis Bvirus. Excisions foundational technologies were developedin the laboratories of Dr. KamelKhaliliat Temple University andDr. JenniferDoudnaatthe University of California, Berkeley.For more information, please visitwww.excision.bio.

Contact:InvestorsJohn Fraunces - LifeSci Advisors917-355-2395jfraunces@lifesciadvisors.com

MediaRobert Flamm, Ph.D.Burns McClellan, Inc.212-213-0006 ext. 364rflamm@burnsmc.com

Link:
Excision BioTherapeutics Awarded California Institute for Regenerative Medicine (CIRM) Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as...

image:For mice placed in chronic jet lag (CJL) conditions, they showed a 68% increase in tumor burden when compared to mice placed in 12 hours of light, 12 hours of darkness (12:12 LD). view more

Credit: Scripps Research

LA JOLLA, CADisruptions in circadian rhythmthe ways that our bodies change in response to the 24-hour light and dark cyclehave been linked to many different diseases, including cancer. The connection between the two has been poorly understood, even though shift workers and others with irregular schedules experience these disruptions regularly. But a new discovery from Scripps Research is helping answer what may be behind this correlation.

Published in Science Advances on September 28, 2022, the findings highlight that chronic circadian disruption significantly increased lung cancer growth in animal models. By identifying the genes implicated, the researchers are illuminating the mysterious link between our sleeping patterns and disease, which could help inform everything from developing more targeted cancer treatments to better monitoring high-risk groups.

There has always been a lot of evidence that shift workers and others with disrupted sleep schedules have higher rates of cancer, and our mission for this study was to figure out why, says senior author Katja Lamia, PhD, associate professor in the Department of Molecular Medicine.

To answer this question, the scientists used a mouse model with expressed KRAS the most commonly mutated gene in lung cancer. Half of the mice were housed in a normal light cycle, meaning 12 hours of light and 12 hours of darkness. The other half were housed in a light cycle meant to resemble that of shift workers, where the light hours were moved earlier by eight hours every two or three days.

The findings aligned with what the researchers initially thought: mice that were exposed to the irregular, shifting light patterns had an increased tumor burden of 68%.

But when they used RNA sequencing to determine the different genes involved in the cancer growth, they were surprised that a collection in the heat shock factor 1 (HSF1) family of proteins was the main culprit.

This is not the mechanism we were expecting to find here. HSF1 has been shown to increase rates of tumor formation in several different models of cancer, but it has never been linked to circadian disruption before, Lamia says.

HSF1 genes are responsible for making sure proteins are still made correctly even when a cell is under extreme stressin this case, when it experiences changes in temperature. The team suspects that HSF1 activity is increased in response to circadian disruption because changes in our sleep cycles disturb the daily rhythms of our bodies temperature.

Normally, our body temperature changes by one or two degrees while were sleeping. If shift workers dont experience that normal drop, it could interfere with how the HSF1 pathway normally operatesand ultimately lead to more dysregulation in the body, Lamia adds. She believes cancer cells may exploit the HSF1 pathway to their own benefit and create mutant, misfolded proteins, but says more research is needed in this area.

These findings help shape not only our understanding of how circadian rhythms impact cancer, but also potentially a preventative way of protecting more vulnerable groups who are at risk. By non-invasive monitoring of body temperature, it may be possible to optimize shift workers schedules and even halt this type of dysregulation that can lead to cancer.

With these discoveries in hand, the scientists are now evaluating if HSF1 signaling is required to increase tumor burden and isnt solely just a correlation.

Now that we know theres a molecular link between HSF1, circadian disruption and tumor growth, its our job to determine how theyre all connected, Lamia says.

In addition to Lamia, authors of the study, Circadian disruption enhances HSF1 signaling and tumorigenesis in Kras-driven lung cancer, include Marie Pariollaud, Lara H. Ibrahim, Emanuel Irizarry, Rebecca M. Mello, Alanna B. Chan, Michael J. Bollong and R. Luke Wiseman of Scripps Research; Brian J. Altman of University of Rochester Medical Center; and Reuben J. Shaw of Salk Institute.

Funding for this research was provided by the National Institutes of Health grant CA211187 (KAL), Brown Foundation for Cancer Research (KAL), National Institutes of Health grant DK107604 (RLW), National Institutes of Health grant R00CA204593 (BJA) and National Science Foundation/DBI-1759544 (EI).

About Scripps Research

Scripps Research is an independent, nonprofit biomedical institute ranked the most influential in the world for its impact on innovation by Nature Index. We are advancing human health through profound discoveries that address pressing medical concerns around the globe. Our drug discovery and development division, Calibr, works hand-in-hand with scientists across disciplines to bring new medicines to patients as quickly and efficiently as possible, while teams at Scripps Research Translational Institute harness genomics, digital medicine and cutting-edge informatics to understand individual health and render more effective healthcare. Scripps Research also trains the next generation of leading scientists at our Skaggs Graduate School, consistently named among the top 10 US programs for chemistry and biological sciences. Learn more atwww.scripps.edu.

Circadian disruption enhances HSF1 signaling and tumorigenesis in Kras-driven lung cancer

28-Sep-2022

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Originally posted here:
The surprising link between circadian disruption and cancer may have to do with temperature - EurekAlert

Pfizer and Sangamo Therapeutics have reopened the recruitment of their phase 3 study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe haemophilia A, the companies announced.

The reopening comes after the two partners voluntarily paused the trial in November 2021 after patients treated with the therapy experienced blood clotting protein Factor VIII activity greater than 150%, raising concerns that they may be at increased risk of harmful clotting events.

The US Food and Drug Administration (FDA) subsequently placed a clinical hold on the trial, before lifting it in March this year. However, the partners kept the voluntary pause in place while working to meet all necessary conditions, including approval of updated trial protocols by regulatory authorities.

People living with haemophilia A lack sufficient functioning Factor VIII protein to help their blood clot. The condition occurs in around one in 5,000 male births annually, and more rarely in females. People with haemophilia can experience bleeding episodes that can cause pain, irreversible joint damage and life-threatening haemorrhages.

The phase 3 AFFINE study is an open-label, multicentre, single arm study to evaluate the efficacy and safety of a single infusion of giroctocogene fitelparvovec in more than 60 adult male participants, aged 18-64 years, with moderately severe to severe haemophilia A.

Eligible study participants will have completed at least six months of routine FVIII prophylaxis therapy during the lead-in phase 3 study in order to collect pretreatment data for efficacy and selected safety parameters, the companies stated.

The primary endpoint in AFFINE is the impact of giroctocogene fitelparvovec on annualised bleeding rate (ABR) after 15 months of follow-up. This will be compared to ABR on prior FVIII prophylaxis replacement therapy.

The secondary endpoints include FVIII activity level after the onset of steady state and after 15 months following infusion of giroctocogene fitelparvovec.

Trial sites will begin to resume enrolment this month, with dosing expected to resume in October and all trial sites anticipated to be active by the end of 2022, the companies outlined.

Giroctocogene fitelparvovec has been granted Orphan Drug, Fast Track and regenerative medicine advanced therapy designations by the FDA, as well as Orphan Medicinal Product designation by the European Medicines Agency.

View post:
Pfizer and Sangamo Therapeutics reopen recruitment for haemophilia A gene therapy trial - PMLiVE

University of Alabama at Birmingham Birmingham, Alabama, United States, 35294 Mayo Clinc Phoenix, Arizona, United States, 85259 Arizona Oncology Associates Tucson, Arizona, United States, 85704 Alliance Research Centers Laguna Hills, California, United States, 92653 VA Greater Los Angeles Healthcare System Los Angeles, California, United States, 90073 University of Southern California Los Angeles, California, United States, 90211 Stanford University Palo Alto, California, United States, 94305 Sharp Memorial Hospital San Diego, California, United States, 92123 Pacific Hematology Oncology Associates San Francisco, California, United States, 94115 San Francisco VA Health Care System San Francisco, California, United States, 94143 UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States, 94158 Redwood Regional Medical Group Santa Rosa, California, United States, 95406 Kaiser Permanente Medical Center (Vallejo) Vallejo, California, United States, 94589 Rocky Mountain Cancer Centers Aurora, Colorado, United States, 80012 Yale School of Medicine New Haven, Connecticut, United States, 06510 4701 Ogletown Stanton Rd. Newark, Delaware, United States, 19713 Georgetown University Medical Center Washington, District of Columbia, United States, 20007 Boca Raton Community Hospital, Inc. Boca Raton, Florida, United States, 33486 Florida Cancer Specialists Fort Myers, Florida, United States, 33980 University of Florida Health Cancer Center Orlando, Florida, United States, 32806 Moffitt Cancer Center Tampa, Florida, United States, 33612 Atlanta Urological Group Atlanta, Georgia, United States, 30312 University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637 Ochsner Medical Center New Orleans, Louisiana, United States, 70121 University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 Walter Reed Hospital Bethesda, Maryland, United States, 48202 Massachusetts General Hospital Boston, Massachusetts, United States, 02114 VA Ann Arbor Healthcare System Ann Arbor, Michigan, United States, 48105 Henry Ford Hospital Detroit, Michigan, United States, 48202 Fairview Hospital Edina, Minnesota, United States, 55435 Minnesota Oncology Hematology, P.A. Minneapolis, Minnesota, United States, 55404 Minnesota Veterans Research Institute Minneapolis, Minnesota, United States, 55417 HCA Midwest Division - Kansas City Kansas City, Missouri, United States, 64132 Alegent Health Bergan Mercy Hospital , GU Research Network Omaha, Nebraska, United States, 68130 Nebraska Cancer Specialists Omaha, Nebraska, United States, 68130 Comprehensive Cancer Centers of Nevada Las Vegas, Nevada, United States, 89119 Premier Urology Associates dba/AdvanceMed Research Lawrenceville, New Jersey, United States, 08648 Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08901 Roswell Park Buffalo, New York, United States, 14263 NYU Perlmutter Cancer Center New York, New York, United States, 10016 Memorial Sloan Kettering CC New York, New York, United States, 10065 Weill Cornell Medical College/NewYork-Presbyterian Hospital New York, New York, United States, 10065 Premier Medical Group of the Hudson Valley PC Poughkeepsie, New York, United States, 12301 University of Rochester Rochester, New York, United States, 14642 SUNY Upstate Medical University Syracuse, New York, United States, 13210 Carolina Urology Partners Concord, North Carolina, United States, 28025 The Urology Group Cincinnati, Ohio, United States, 45212 Kettering Cancer Center Kettering, Ohio, United States, 45429 Clinical Research Solutions Middleburg Heights, Ohio, United States, 44130 VA Portland Health Care System Portland, Oregon, United States, 97219 Consultants in Medical Oncology Hematology Horsham, Pennsylvania, United States, 19044 SCRI - Tennessee Oncology Nashville, Tennessee, United States, 37203 Texas Oncology Medical City Dallas Dallas, Texas, United States, 75320 UT Southwestern Medical Center Dallas, Texas, United States, 75390 UT Health Science Center Houston, Texas, United States, 77030 Texas Oncology - Tyler Tyler, Texas, United States, 75702 Virginia Oncology Associates Norfolk, Virginia, United States, 23502 VA Puget Sound Seattle, Washington, United States, 98108 Northern Cancer Insitute, St. Leonards Saint Leonards, New South Wales, Australia, 2065 Royal Hobart Hospital Hobart, Tasmania, Australia, 7000 Peninsula & Southeast Oncology Frankston, Victoria, Australia, 3199 Barwon Health, University Hospital Geelong Geelong, Victoria, Australia, 3220 Cabrini Hospital Malvern, Victoria, Australia, 3144 Southside Cancer Care Centre Miranda, Australia, 2228 Orange Health Services Orange, Australia, 2800 St John of God Hospital, Subiaco Subiaco, Australia, 6008 Riverina Cancer Care Centre Wagga Wagga, Australia, 2650 ZNA Middelheim Antwerp, Belgium, 2020 Universitair Ziekenhuis Gent Gent, Belgium, B-9000 AZ Groeninge Kortrijk, Belgium, 8500 CHU Sart-Tilman Lige, Belgium, 4000 Equipe de Recherche Clinique, Dpartement d'Oncologie/Hmatologie Lige, Belgium, 4000 AZ DELTA Roeselare, Belgium, B-8800 Juravinski Cancer Centre Hamilton Health Services Hamilton, Ontario, Canada, L8V5C2 London Health Science Center - Victoria Hospital London, Ontario, Canada, N6A 4L6 The Ottawa Hospital Ottawa, Ontario, Canada, K1H8L6 Princess Margaret Hospital Toronto, Canada, M5G 2M9 Copenhagen University Hospital Copenhagen, Denmark, 2100 Herlev Hospital Herlev, Denmark, 2730 Vejle Sygehus Vejle, Denmark, 7100 Centre Franois Baclesse Caen, France, 14000 Centre Georges Franois Leclerc Dijon, France, 21079 Clinique Victor Hugo Centre Jean Bernard Le Mans, France, 72000 Hpital Priv La Louvire Lille, France, 59800 Polyclinique de Gentilly (Centre D'Oncologie De Gentilly) Nancy, France, 54100 Institut Curie Paris, France, 75248 Hpital Priv des Ctes d'Armor Plrin, France, 22190 CRLCC Eugene Marquis Rennes, France, 35042 Gemeinschaftspraxis fur Hamatologie & Onkologie Augsburg, Germany, 86150 Charite Universitatsmedizin Berlin Berlin, Germany, 12200 Universitatsklinikum Carl Gustav Carus Dresden, Germany, 01307 Universitatsklinikum Dusseldorf Dusseldorf, Germany, 40225 Urologische Gemeinschaftspraxis Emmendingen, Germany, 79312 Universitaetsklinikum Hamburg-Eppendorf (UKE) Hamburg, Germany, 20246 Universitaetsklinikum Heidelberg Heidelberg, Germany, 69120 Universitatsklinikum Jena Jena, Germany, 07747 Universittsklinik Kln Kln, Germany, 50937 Universittsklinikum Schleswig-Holstein Lbeck, Germany, 23538 Medizinischen Fakultt Mannheim der Universitt Heidelberg Mannheim, Germany, 68167 Studienpraxis Urologie Nrtingen, Germany, 72622 University of Tuebingen Tuebingen, Germany, 72076 Die Gesundhehitsunion DGU Wuppertal, Germany, 42103 Cork University Hospital Cork, Ireland, T12 DFK4 St. Vincent's University Hospital Dublin, Ireland, D04T6F4 St James's Hospital Dublin, Ireland, D08 NHY1 Adelaide & Meath Hospital, Incorporating the National Children's Hospital Dublin, Ireland, Dublin 24 Mater Misericordiae University Hospital Dublin, Ireland, Dublin 7 Rambam Health Care Campus (RHCC), Rambam Medical Center Haifa, Israel, 3109601 Hadassah University Hospital Jerusalem, Israel, 71120 Meir Medical Center Kfar Saba, Israel, 4428164 Rabin Medical Center-Beilinson Campus Petach Tikva, Israel, 4941492 Chaim Sheba Medical Center Ramat Gan, Israel, 52621 The Tel Aviv Sourasky Medical Center (Ichilov Hospital) Tel Aviv, Israel, 64231 Ospedale San Donato, Azienda USLSUDEST Arezzo, Italy, 52100 Ospedale Santa Maria delle Croci Faenza, Italy, 48018 IRCCS Istituto Nazionale dei Tumori (INT) Milano, Italy, 20133 IEO Instituto Europeo di Oncologia Milano, Italy, 20141 University of Modena and Reggio Emilia Medical Oncology Modena, Italy, 41124 Azienda Ospedaliera San Camillo-Forlanini Rome, Italy, 00152 Azienda Opsedaliera S. Maria di Terni Terni, Italy, 05100 Santa Chiara Hospital, Dept Medical Oncology Trento, Italy, 38122 Hospital Universitari Germans Trias i Pujol Badalona, Spain, 08916 Hospital del Mar, Servicio de Oncologa Barcelona, Spain, 08003 Hospital Clnic i Provincial de Barcelona-Oncology Barcelona, Spain, 08036 Instituto Catalan de Oncologia Barcelona, Spain, 08908 Hospital Universitari Germans Trias i Pujol Barcelona, Spain, 08916 Hospital General Universitario de Guadalajara Guadalajara, Spain, 19002 Hospital Universitario Lucus Augusti. Lugo, Spain, 27003 MD Anderson Cancer Center - Madrid Madrid, Spain, 28033 Hospital Universitario Ramn y Cajal Madrid, Spain, 28034 Hospital 12 de Octubre Madrid, Spain, 28041 Hospital Universitario La Paz Madrid, Spain, 28046 Hospital Puerta de Hierro-Majadahonda Madrid, Spain, 28222 Hospital Universitario Central de Asturias Oviedo, Spain, 33011 Corporacio Sanitaria Parc Tauli Sabadell, Spain, 8208 Marques de Valdecilla University Hospital (HUMV) Santander, Spain, 39008 Hospital Universitario Virgen del Roco Sevilla, Spain, 41013 Instituto Valenciano de Oncologia IVO Valencia, Spain, 46009 Wexham Park Hospital Slough, Berkshire, United Kingdom, SL2 4HL Mount Vernon Cancer Centre Northwood, England, United Kingdom, HA6 2RN Royal Marsden Hospital Sutton, Surrey, United Kingdom, SM2 5PT Oxford University Hospitals Headington, United Kingdom, OC3 7LJ Royal Liverpool Hospital Liverpool, United Kingdom, L7 8XP London Health Science Center - Victoria Hospital London, United Kingdom, N6A 4L6 Guy's Hospital London, United Kingdom, SE1 9RT Sarah Cannon Research Institutute - UK London, United Kingdom, W1G 6AD Southampton General Hospital Southampton, United Kingdom, SO16 6YD Musgrove Park Hospital Taunton, United Kingdom, TA1 5DA The Clatterbridge Cancer Centre NHS Foundation Trust Wirral, United Kingdom, CH63 4JY

Originally posted here:
A Study of Rucaparib in Patients With Metastatic Castration-resistant ...